Large B-cell lymphoma (LBCL) spans the gamut of aggressive lymphoid tumors with extensive biologic and clinical heterogeneity. Most patients with LBCL are cured with the use of front-line chemoimmunotherapy, yet approximately 40% have a relapse.1 Although second-line CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for persistent or early…
The New England Journal of Medicine: Search Results in Hematology/Oncology
